Dose-finding Study for AdimrSC-2f Vaccine

Summary

AdimrSC-2f is a subunit protein-based vaccine produced using the baculovirus insect cells manufacturing process to prevent Coronavirus disease 2019 (COVID-19). The primary goal of this Phase I/II study is to evaluate the vaccine safety and immunogenicity of AdimrSC-2f in healthy adult individuals, as compared to placebo.

Timeline

Start

2022-01-03

Primary completion

2022-12-29

Completion

2023-07-26

Drugs

Indications